X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (310) 310
hematology (213) 213
male (210) 210
female (202) 202
oncology (199) 199
index medicus (194) 194
middle aged (186) 186
adult (176) 176
aged (147) 147
antineoplastic combined chemotherapy protocols - therapeutic use (104) 104
treatment outcome (99) 99
chemotherapy (90) 90
rituximab (82) 82
prognosis (74) 74
disease-free survival (73) 73
lymphomas (70) 70
non-hodgkins-lymphoma (68) 68
aged, 80 and over (61) 61
retrospective studies (60) 60
antineoplastic agents - therapeutic use (51) 51
cancer (50) 50
neoplasm staging (50) 50
therapy (50) 50
classification (49) 49
lymphoma (49) 49
recurrence (48) 48
survival analysis (48) 48
adolescent (46) 46
remission induction (46) 46
lymphoma, non-hodgkin - drug therapy (42) 42
hemic and lymphatic diseases (41) 41
cyclophosphamide - administration & dosage (40) 40
combined modality therapy (39) 39
follicular lymphoma (39) 39
antineoplastic combined chemotherapy protocols - administration & dosage (38) 38
disease (36) 36
hematology, oncology and palliative medicine (36) 36
vincristine - administration & dosage (36) 36
phase-ii (35) 35
care and treatment (34) 34
prednisone - administration & dosage (33) 33
survival (33) 33
young adult (33) 33
follow-up studies (32) 32
brentuximab vedotin (31) 31
doxorubicin - administration & dosage (31) 31
b-cell lymphoma (29) 29
fludarabine (28) 28
immune system diseases (27) 27
transplantation (27) 27
vidarabine - analogs & derivatives (27) 27
lymphoma, large b-cell, diffuse - drug therapy (26) 26
analysis (25) 25
cyclophosphamide (25) 25
patients (25) 25
survival rate (25) 25
trial (25) 25
abridged index medicus (24) 24
antibodies, monoclonal - therapeutic use (24) 24
phase-ii trial (23) 23
antineoplastic agents (22) 22
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
bleomycin - administration & dosage (22) 22
cancer research (22) 22
drug administration schedule (22) 22
hodgkin disease - drug therapy (22) 22
non-hodgkin's lymphomas (22) 22
salvage therapy (22) 22
antineoplastic agents - adverse effects (21) 21
chronic lymphocytic-leukemia (21) 21
radiotherapy (21) 21
response criteria (21) 21
time factors (21) 21
high-dose chemotherapy (20) 20
malignant-lymphoma (20) 20
positron-emission-tomography (20) 20
hodgkin's disease (19) 19
radioimmunotherapy (19) 19
t cells (19) 19
antibodies, monoclonal, murine-derived (18) 18
follow-up (18) 18
gemcitabine (18) 18
hematopoietic stem cell transplantation (18) 18
italy (18) 18
lymphoma, large b-cell, diffuse - pathology (18) 18
macop-b (18) 18
stem cell transplantation (18) 18
vidarabine - administration & dosage (18) 18
antibodies, monoclonal, murine-derived - administration & dosage (17) 17
antineoplastic combined chemotherapy protocols (17) 17
diffuse large b-cell lymphoma (17) 17
hodgkin disease - pathology (17) 17
leukemia (17) 17
lymphoma, large b-cell, diffuse - mortality (17) 17
lymphoma, non-hodgkin - mortality (17) 17
lymphoma, non-hodgkin - therapy (17) 17
prednisone (17) 17
research (17) 17
transplantation, autologous (17) 17
antibodies, monoclonal - administration & dosage (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4779 - 4779
Abstract BACKGROUND: Axicabtagene ciloleucel (axi-cel) is a CD19-directed chimeric antigenic receptor (CAR) T-cell therapy which has been approved by FDA for... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1548 - 1548
Background: The prognosis is poor for most patients with lymphoma who do not respond to initial therapy, leaving an unmet need for effective therapies for this... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5263 - 5263
To assess the efficacy of radioimmunotherapy (RIT) with 90yttrium-ibrutinib-tiuxetan (90Y-IT) in mantle cell lymphoma, data from 90 patients registered in the... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5252 - 5252
Background: Bruton tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling, which mediates B-cell proliferation, migration, and adhesion.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5322 - 5322
Abstract Background: Idelalisib (Zydelig®, IDELA), an oral agent, and copanlisib (Aliqopa®, COPA), an intravenous agent, are the only B-cell receptor pathway... 
Journal Article
Hematological Oncology, ISSN 0278-0232, 12/2017, Volume 35, Issue 4, pp. 909 - 910
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4161 - 4161
Abstract Background: Bruton's tyrosine kinase (BTK) has a key role in B-cell receptor mediated pathways that are implicated in the pathogenesis of several... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2920 - 2920
Abstract Older age (≥60 years) has consistently been identified as an independent adverse prognostic factor for Hodgkin lymphoma (HL) survival in... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4135 - 4135
Background: In February 2017, CT-P10 became the first rituximab biosimilar to be approved in Europe for treatment of rheumatic diseases and specific blood... 
Journal Article
Hematological oncology, ISSN 0278-0232, 07/2019
Follicular lymphoma is an indolent B cells proliferative disorder that represent approximately 35 percent of all non-Hodgkin's lymphomas. Although spontaneous... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2098 - 2098
Abstract Background: Veno-Occlusive Disease (VOD) or Sinusoidal Obstruction syndrome (SOS), is a rare but potentially life-threatening complication after... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2241 - 2241
Abstract Introduction: DLBCL is an aggressive form of non-Hodgkin lymphoma (NHL) occurring more frequently in older patients (pts). Frontline treatment usually... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1716 - 1716
Abstract BACKGROUND: The objective of this study was to evaluate the effectiveness and safety of pixantrone as a rescue treatment for NHL patients in a real... 
Journal Article
International Reviews of Immunology, ISSN 0883-0185, 03/2019, Volume 38, Issue 2, pp. 79 - 91
Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL,... 
novel method | promoting | Enhancing efficiency | non-Hodgkin lymphoma | pretargeting | radioimmunotherapy
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 1647 - 1647
Abstract Introduction: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in AYAs, defined in the United States as patients 15 to 39 years of age.... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4167 - 4167
Abstract Introduction: Indolent NHL (iNHL) remains largely incurable, with the majority of patients (pts) eventually becoming refractory to standard therapies,... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.